122 related articles for article (PubMed ID: 8151321)
1. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.
Nadali G; Vinante F; Ambrosetti A; Todeschini G; Veneri D; Zanotti R; Meneghini V; Ricetti MM; Benedetti F; Vassanelli A
J Clin Oncol; 1994 Apr; 12(4):793-7. PubMed ID: 8151321
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
Zinzani PL; Pileri S; Bendandi M; Buzzi M; Sabattini E; Ascani S; Gherlinzoni F; Magagnoli M; Albertini P; Tura S
J Clin Oncol; 1998 Apr; 16(4):1532-7. PubMed ID: 9552063
[TBL] [Abstract][Full Text] [Related]
4. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.
Nadali G; Tavecchia L; Zanolin E; Bonfante V; Viviani S; Camerini E; Musto P; Di Renzo N; Carotenuto M; Chilosi M; Krampera M; Pizzolo G
Blood; 1998 Apr; 91(8):3011-6. PubMed ID: 9531614
[TBL] [Abstract][Full Text] [Related]
5. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
[TBL] [Abstract][Full Text] [Related]
6. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage.
Pizzolo G; Vinante F; Chilosi M; Dallenbach F; Josimovic-Alasevic O; Diamantstein T; Stein H
Br J Haematol; 1990 Jun; 75(2):282-4. PubMed ID: 2164839
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
Heshmat NM; El-Hadidi ES
Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
[TBL] [Abstract][Full Text] [Related]
10. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis.
Vener C; Guffanti A; Pomati M; Colombi M; Alietti A; La Targia ML; Bamonti-Catena F; Baldini L
Leuk Lymphoma; 2000 Apr; 37(3-4):333-9. PubMed ID: 10752984
[TBL] [Abstract][Full Text] [Related]
11. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD30 and cyclosporine in severe atopic dermatitis.
Caproni M; Salvatore E; Cardinali C; Brazzini B; Fabbri P
Int Arch Allergy Immunol; 2000 Apr; 121(4):324-8. PubMed ID: 10828723
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent changes of serum soluble CD30 concentration in children.
Chrul S; Polakowska E
Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
15. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
[TBL] [Abstract][Full Text] [Related]
16. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
Truong DQ; Darwish AA; Gras J; Wieërs G; Cornet A; Robert A; Mourad M; Malaise J; de Ville de Goyet J; Reding R; Latinne D
Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
[TBL] [Abstract][Full Text] [Related]
17. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
Altermann W; Schlaf G; Rothhoff A; Seliger B
Nephrol Dial Transplant; 2007 Oct; 22(10):2795-9. PubMed ID: 17616534
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD30 as a prognostic factor for outcome following renal transplantation.
Platt RE; Wu KS; Poole K; Newstead CG; Clark B
J Clin Pathol; 2009 Jul; 62(7):662-3. PubMed ID: 19561239
[TBL] [Abstract][Full Text] [Related]
19. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluticasone propionate on soluble CD30 release in patients with severe allergic asthma.
Purello-D'Ambrosio F; Gangemi S; Ruello G; Marotta G; Merendino RA
J Investig Allergol Clin Immunol; 2000; 10(5):283-5. PubMed ID: 11108439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]